Thalassemia in India

References

• Verma IC, Saxena R, Kohli S. Past, present and future scenario of thalassemia care and control in India. Indian J Med Res. 2011;134(4):507–521.
   PubMedGoogle Scholar
• Colah RB, Italia KY, Gorakshakar AC. Burden of thalassemia in India and the roadmap for control. Pediatr Hematol Oncol. J. 2017;2(4):79–84.
   Google Scholar
• Paltasingh T, Paliwal G. Tribal population in India: regional dimensions and imperatives. J Regional Dev Plan. 2014;3(2):27–35.
   Google Scholar
• Narian JP. Public health challenges in India: seizing the opportunities. Indian J Community Med. 2016;41(2):85–88.
   PubMedGoogle Scholar
• Kantharaj A, Chandrashekar S. Coping with the burden of thalassemia: aiming for a thalassemia free world. Glob J Transfus Med. 2018;3(1):1–5.
   Google Scholar
• Madan N, Sharma S, Sood SK, et al. Frequency of β-thalassemia trait and other hemoglobinoapthies in northern and western India. Indian J Hum Genet. 2010;16(1):16–25.
   PubMedGoogle Scholar
• Dolai TK, Dutta S, Bhattacharyya M, et al. Prevalence of hemoglobinopathies in rural Bengal, India. Hemoglobin. 2012;36(1):57–63.
   PubMed Web of Science ®Google Scholar
• Mohanty D, Colah RB, Gorakshakar A, et al. Prevalence of β thalassemia and other hemoglobinopathies in six cities in India: a multicentre study. J Community Genet. 2013;4(1):33–42.
   PubMedGoogle Scholar
• Patel AP, Patel RB, Patel SA, et al. β Thalassemia mutations in western India: outcome of prenatal diagnosis in a hemoglobinopathies project. Hemoglobin. 2014;38(5):329–334.
   PubMed Web of Science ®Google Scholar
• Choudhuri S, Sen A, Ghosh MK, et al. Effectiveness of prenatal screening for hemoglobinopathies in a developing country. Hemoglobin. 2015;39(6):380–383.
   PubMed Web of Science ®Google Scholar
• Chatterjee T, Chakravarty A, Chakravarty S. Population screening and prevention strategies for thalassemia and other hemoglobinopathies in Eastern India: experience of 18,166 cases. Hemoglobin. 2015;39(6):384–388.
   PubMed Web of Science ®Google Scholar
• Mendiratta SL, Mittal M, Naaz F, et al. Role of thalassemia screening in prevention and control of thalassemia – a 5 year experience. Int J Reprod Concept Obstet Gynecol. 2016;5(9):3017–3111.
   Google Scholar
• Teli AB, Deori R, Saikia SP. Hemoglobinopathies and β thalassemia among tribals working in the tea gardens of Assam, India. J Clin Diagn Res. 2016;10(12):LC19–LC22.
   PubMed Web of Science ®Google Scholar
• Colah R, Gorakshakar A, Phanasgaonkar S, et al. Epidemiology of beta-thalassaemia in Western India: mapping the frequencies and mutations in sub-regions of Maharashtra and Gujarat. Br J Haematol. 2010;149(5):739–747.
   PubMed Web of Science ®Google Scholar
• Nadkarni A, Phanasgaonkar S, Colah R, et al. Prevalence and molecular characterization of alpha-thalassemia syndromes among Indians. Genet Test. 2008;12(2):177–180.
   PubMedGoogle Scholar
• Colah R, Mukherjee M, Ghosh K. Sickle cell disease in India. Curr Opin Hematol. 2014;21(3):215–223.
   PubMed Web of Science ®Google Scholar
• Patra PK, Khodiar PK, Hambleton IR, et al. The Chhattisgarh state screening programme for the sickle cell gene: a cost-effective approach to a public health problem. J Community Genet. 2015;6(4):361–368.
   PubMed Web of Science ®Google Scholar
• Colah RB, Ghosh K, Editors. Compendium of Hemoglobinopathies in India. Division of Publication and Information, Indian Council of Medical Research. New Delhi, India, 2016.
   Google Scholar
• Warghade S, Britto J, Haryan R, et al. Prevalence of hemoglobin variants and hemoglobinopathies using cation-exchange high-performance liquid chromatography in a central reference laboratory of India: A report of 65779 cases. J Lab Physicians. 2018;10(1):73–79.
   PubMed Web of Science ®Google Scholar
• Sharma P. Summary and review of the abstracts on Disorders of Red Cells and Erythropoiesis presented at the Annual Conferences of the Indian Society of Haematology and Blood Transfusion, Jaipur, India on November 10-13 2016 and Guwahati, India on November 2-5 2017. (Haematocon 2016-17). Indian J Haematol Blood Trans. 2018;34(1):8–12.
   PubMed Web of Science ®Google Scholar
• Garewal G, Fearon CW, Warren TC, et al. The molecular basis of beta thalassaemia in Punjabi and Maharashtran Indians includes a multilocus aetiology involving triplicated alpha-globin loci. Br J Haematol. 1994;86(2):372–376.
   PubMed Web of Science ®Google Scholar
• Verma IC, Saxena R, Thomas E, et al. Regional distribution of beta-thalassemia mutations in India. Hum Genet. 1997;100(1):109–113.
   PubMed Web of Science ®Google Scholar
• Edison ES, Shaji RV, Devi SG, et al. Analysis of beta globin mutations in the Indian population: presence of rare and novel mutations and region-wise heterogeneity. Clin Genet. 2008;73(4):331–337.
   PubMed Web of Science ®Google Scholar
• Colah R, Gorakshakar A, Nadkarni A, et al. Regional heterogeneity of beta-thalassemia mutations in the multi ethnic Indian population. Blood Cells Mol Dis. 2009;42(3):241–246.
   PubMed Web of Science ®Google Scholar
• Sinha S, Black ML, Agarwal S, et al. Profiling β-thalassaemia mutations in India at state and regional levels: implications for genetic education, screening and counselling programmes. Hugo J. 2009;3(1-4):51–62.
   PubMedGoogle Scholar
• Kumar R, Arya V, Agarwal S. Profiling β thalassemia mutations in consanguinity and nonconsanguinity for prenatal screening and awareness programme. Adv Hematol. 2015;2015:625721.
   PubMedGoogle Scholar
• Nadkarni AH, Gorakshakar AC, Sawant PM, et al. The phenotypic and molecular diversity of hemoglobinopathies in India: a review of 15 years at a referral center. Int J Lab Hematol. 2019;41(2):218–226.
   PubMed Web of Science ®Google Scholar
• Das R, Fisher C, Kaur J, et al. Wide spectrum of molecular and clinical heterogeneity in Hb H disease in North Indian patients. [Abstract] Presented at the 56th American Society of Hematology meeting held at San Francisco, CA, USA on December 6-9 2014. Blood. 2014;124(21):1358–1358.
   Google Scholar
• Deshpande P, Kamalanathan N, Sampath E, et al. Characterization and clinical and laboratory profiles of the deletional α2-globin gene polyadenylation signal sequence (AATAAA>AATA– –) in an Indian population. in an Indian Population. Hemoglobin. 2015;39(6):415–418.
   PubMed Web of Science ®Google Scholar
• Gorivale M, Sawant P, Mehta P, et al. Challenges in prenatal diagnosis of beta thalassaemia: couples with normal HbA2 in one partner. Prenat Diagn. 2015;35(13):1353–1357.
   PubMed Web of Science ®Google Scholar
• Jain S, Edison ES, Mathews V, et al. A novel δ-globin gene mutation (HBD: c.323G>A) masking the diagnosis of β-thalassemia: a first report from India. Int J Hematol. 2012;95(5):570–572.
   PubMed Web of Science ®Google Scholar
• Colaco S, Colah R, Ghosh K, et al. Compromising for carrier detection of beta thalassemia based on measurement of HbA2 levels in unusual cases. Clin Chim Acta. 2012;413(19–20):1705–1707.
   PubMed Web of Science ®Google Scholar
• Colaco S, Trivedi A, Colah RB, et al. Masking of a β-thalassemia determinant by a novel δ-globin gene defect [Hb A2-Saurashtra or δ100(G2)Pro→Ser; HBD: c.301C>T] in cis. Hemoglobin. 2014;38(1):24–27.
   PubMed Web of Science ®Google Scholar
• Hariharan P, Colaco S, Colah R, et al. Delta globin gene variations leading to reduction in HbA2 levels. Int J Lab Hematol. 2016;38(6):610–615.
   PubMed Web of Science ®Google Scholar
• Moirangthem A, Phadke SR. Socio-demographic profile and economic burden of treatment of transfusion dependent thalassemia. Indian J Pediatr. 2018;85(2):102–107.
   PubMed Web of Science ®Google Scholar
• Sinha S, Seth T, Colah RB, et al. Haemoglobinopathies in India: estimates of blood requirements and treatment costs for the decade 2017-2026. J Community Genet. 2020;11(1):39–45.
   PubMed Web of Science ®Google Scholar
• Bhatia P, Nagar V, Meena JS, et al. A study on the demographic and morbidity patterns of thalassemia patients registered at a tertiary-care center of central India. Int J Med Sci Public Health. 2015;4(1):85–88.
   Google Scholar
• Mallik S, Chatterjee C, Mandal PK, et al. Expenditure to treat thalassaemia: an experience at a tertiary care hospital in India. Iranian J Public Health. 2010;39(1):78–84.
   PubMed Web of Science ®Google Scholar
• Esmaeilzadeh F, Azarkeivan A, Emamgholipour S, et al. Economic burden of thalassemia major in Iran, 2015. J Res Health Sci. 2016;16(3):111–115.
   PubMedGoogle Scholar
• Riewpaiboon A, Nuchprayoon I, Torcharus K, et al. Economic burden of beta-thalassemia/Hb E and beta-thalassemia major in Thai children. BMC Res Notes. 2010;3:29.
   PubMedGoogle Scholar
• Ahmadnezhad E, Sepehrvand N, Jahani FF, et al. Evaluation and cost analysis of national health policy of thalassaemia screening in west-azerbaijan province of iran. Int J Prev Med. 2012;3(10):687–692.
   PubMedGoogle Scholar
• Ginsberg G, Tulchinsky T, Filon D, et al. Cost-benefit analysis of a national thalassaemia prevention programme in Israel. J Med Screen. 1998;5(3):120–126.
   PubMed Web of Science ®Google Scholar
• Koren A, Profeta L, Zalman L, et al. Prevention of β thalassemia in Northern Israel – a cost-benefit analysis. Mediterr J Hematol Infect Dis. 2014;6(1):e2014012.
   PubMedGoogle Scholar
• Sheth S, Weiss M, Parisi M, et al. Clinical and economic burden of transfusion-dependent β-thalassemia in adult patients in the United States. Blood. 2017;130(Suppl 1):2095.
   Google Scholar
• Ho W-L, Lin K-H, Wang J-D, et al. Financial burden of national health insurance for treating patients with transfusion-dependent thalassemia in Taiwan. Bone Marrow Transplant. 2006;37(6):569–574.
   PubMed Web of Science ®Google Scholar
• Mathews V, Balasubramanian P, Abraham A, et al. Allogeneic stem cell transplant for thalassemia major in India. Pediatr Hematol Oncol J. 2017;2(4):114–120.
   Google Scholar
• Kulkarni U, George B. Access to hematopoietic stem-cell transplantation in India. J Postgrad Med. 2019;65(1):1–4.
   PubMed Web of Science ®Google Scholar
• Joseph John M, Jyani G, Jindal A, et al. Cost effectiveness of hematopoietic stem cell transplantation compared with transfusion chelation for treatment of thalassemia major. Biol Blood Marrow Transplant. 2018;24(10):2119–2126.
   PubMed Web of Science ®Google Scholar
• Weidlich D, Kefalas P, Guest JF. Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016;56(5):1038–1045.
   PubMed Web of Science ®Google Scholar